Navigation Links
Neurocrine Announces Proposed Public Offering of Common Stock
Date:3/4/2010

SAN DIEGO, March 4 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it is offering to sell shares of its common stock in an underwritten public offering.  Jefferies & Company, Inc. is the sole book-running manager for this offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The securities described above are being offered by Neurocrine pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC") on December 3, 2007. A preliminary prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's Web site at http://www.sec.gov. Copies of the preliminary prospectus supplement relating to these securities may be obtained from Jefferies & Company, Inc., Attention: Syndicate Prospectus Department, 520 Madison Avenue, New York, NY, 10022 and at (888) 449-2342. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine-related diseases and disorders.

In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties such as those, among others, relating to Neurocrine's expectations regarding the completion, timing and size of its proposed public offeringAmong the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as risks and uncertainties associated with Neurocrine's business and finances in general, and the other risks described in Neurocrine's annual report on Form 10-K for the year ended December 31, 2009. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

SOURCE Neurocrine Biosciences, Inc.

Back to top

RELATED LINKS
http://www.neurocrine.com

'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Neurocrine Biosciences Reports First Quarter 2008 Results
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
6. Neurocrine Biosciences Presents Elagolix Data
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
8. Neurocrine Biosciences Reports Third Quarter 2009 Results
9. Neurocrine Advances VMAT2 Inhibitor Program
10. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2020)... (PRWEB) , ... May 30, 2020 , ... During a ... is not an inherent trait - it is developed and strengthened through hardship. Recent ... type of mindset, and engage in certain practices in order to stay strong in ...
(Date:5/28/2020)... ... May 28, 2020 , ... ... hospital, and an Alliance member of the Cleveland Clinic Heart, Vascular & Thoracic ... chronic obstructive pulmonary disease (COPD). , COPD is a growing and devastating disease ...
(Date:5/28/2020)... (PRWEB) , ... May 28, 2020 , ... ... continuum, The Beryl Institute releases its latest white paper, Caring for our Children: ... of successful patient experience practices in pediatric settings and highlights key findings to ...
Breaking Medicine Technology:
(Date:6/5/2020)... ... June 05, 2020 , ... Help.org, a trusted online resource for individuals ... in New York, New York for 2020. The informational guide recognizes the top 10 ... According to recent studies, drug overdose is the leading cause of death among people ...
(Date:6/4/2020)... BRENTWOOD, Tenn. (PRWEB) , ... June 04, 2020 ... ... behavioral health and substance abuse treatment services has announced the addition of the ... will be integrated into the larger treatment curriculum at each facility to provide ...
(Date:6/2/2020)... ... 02, 2020 , ... RemetricHealth , a leading remote ... industry for more than a decade, announced today the launch of its new ... 2010, RemetricHealth, then known as PMD Healthcare, developed the first-ever patented, FDA-approved at-home ...
(Date:5/30/2020)... ... May 29, 2020 , ... In appreciation for all the dedication ... James Hodge Hyundai is offering a $500 bonus towards the lease or purchase of ... now through January 4, 2021. , To qualify for this offer, individuals must be ...
(Date:5/28/2020)... (PRWEB) , ... May 28, 2020 , ... ... to fully re-open in the fall, operators of student housing are scrambling to ... return. COCM, which manages over 37,000 student housing beds on 38 campuses across ...
Breaking Medicine News(10 mins):